HRP20180124T1 - Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba - Google Patents

Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba Download PDF

Info

Publication number
HRP20180124T1
HRP20180124T1 HRP20180124TT HRP20180124T HRP20180124T1 HR P20180124 T1 HRP20180124 T1 HR P20180124T1 HR P20180124T T HRP20180124T T HR P20180124TT HR P20180124 T HRP20180124 T HR P20180124T HR P20180124 T1 HRP20180124 T1 HR P20180124T1
Authority
HR
Croatia
Prior art keywords
chemically modified
glycosaminoglycan
hours
heparin
kda
Prior art date
Application number
HRP20180124TT
Other languages
English (en)
Croatian (hr)
Inventor
Hans-Peter Ekre
Per-Olov ERIKSSON
Ulf Lindahl
Erik Holmer
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180124(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of HRP20180124T1 publication Critical patent/HRP20180124T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HRP20180124TT 2011-12-19 2012-12-19 Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba HRP20180124T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
EP12858809.2A EP2794665B1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (1)

Publication Number Publication Date
HRP20180124T1 true HRP20180124T1 (hr) 2018-02-23

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180124TT HRP20180124T1 (hr) 2011-12-19 2012-12-19 Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba

Country Status (28)

Country Link
US (1) US9475888B2 (enExample)
EP (1) EP2794665B1 (enExample)
JP (2) JP6543467B2 (enExample)
KR (1) KR102135485B1 (enExample)
CN (1) CN104144950B (enExample)
AU (1) AU2012354229B2 (enExample)
BR (1) BR112014014454B1 (enExample)
CA (1) CA2856492C (enExample)
CL (1) CL2014001651A1 (enExample)
CO (1) CO7061069A2 (enExample)
CY (1) CY1119899T1 (enExample)
DK (1) DK2794665T3 (enExample)
ES (1) ES2656613T3 (enExample)
HR (1) HRP20180124T1 (enExample)
HU (1) HUE036523T2 (enExample)
IL (1) IL232905A (enExample)
LT (1) LT2794665T (enExample)
ME (1) ME02994B (enExample)
MX (1) MX351104B (enExample)
NO (1) NO2904345T3 (enExample)
PL (1) PL2794665T3 (enExample)
PT (1) PT2794665T (enExample)
RS (1) RS56874B1 (enExample)
RU (1) RU2617764C2 (enExample)
SI (1) SI2794665T1 (enExample)
SM (1) SMT201800143T1 (enExample)
WO (1) WO2013095279A1 (enExample)
ZA (1) ZA201403640B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2868479A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
RU2014143017A (ru) * 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов
WO2013169194A1 (en) * 2012-05-08 2013-11-14 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
KR20170013255A (ko) * 2014-04-30 2017-02-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 헤파란 설페이트
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
AU2021223494B2 (en) 2020-02-17 2026-01-08 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
WO2023213788A1 (en) 2022-05-03 2023-11-09 Dilafor Ab New medical use of tafoxiparin
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (en) * 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
DE69623840D1 (de) * 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Zusammensetzung zur Hemmung der Thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) * 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
JP3342007B2 (ja) * 1997-11-20 2002-11-05 郁男 山科 低分子ヘパリン修飾体及び皮膚潰瘍治療剤
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
US6492503B1 (en) * 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
WO2000013019A1 (en) * 1998-08-26 2000-03-09 The Collaborative Group, Ltd. Receptor for underivatized, aqueous soluble beta-(1,3)-glucan
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DE60138115D1 (de) * 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
EP1906975A4 (en) 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
CN101432626B (zh) * 2006-04-04 2013-06-19 神谷来克斯公司 用于肌钙蛋白分析的高灵敏系统和方法
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
RU2010122324A (ru) * 2007-11-02 2011-12-10 Момента Фармасьютикалз, Инк. (Us) Полисахаридные композиции, не обладающие антикоагулянтными свойствами
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
US8680200B2 (en) * 2009-03-27 2014-03-25 Actamax Surgical Materials Llc Polyglycerol aldehydes
US20120183976A1 (en) 2009-04-16 2012-07-19 He Zhou Methods of assessing activity of a polysaccharide composition
AU2010268756A1 (en) 2009-06-30 2012-01-19 The Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
EA201290069A1 (ru) * 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
JP5796860B2 (ja) * 2009-12-22 2015-10-21 ライフボンド リミテッドＬｉｆｅｂｏｎｄ Ｌｔｄ 架橋マトリックスの特性を調節するための酵素的架橋剤の改変
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2014143017A (ru) 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов
CA2868479A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
EP2794665B1 (en) 2017-11-22
KR20140113652A (ko) 2014-09-24
MX2014007122A (es) 2015-03-05
CA2856492A1 (en) 2013-06-27
PT2794665T (pt) 2018-01-24
AU2012354229B2 (en) 2016-12-01
RS56874B1 (sr) 2018-04-30
HUE036523T2 (hu) 2018-07-30
HK1202883A1 (en) 2015-10-09
DK2794665T3 (da) 2018-01-29
LT2794665T (lt) 2017-12-27
BR112014014454A2 (pt) 2017-06-13
CO7061069A2 (es) 2014-09-19
SI2794665T1 (en) 2018-03-30
ME02994B (me) 2018-10-20
ES2656613T3 (es) 2018-02-27
EP2794665A4 (en) 2015-08-26
KR102135485B1 (ko) 2020-07-17
PL2794665T3 (pl) 2018-04-30
CY1119899T1 (el) 2018-06-27
CA2856492C (en) 2017-01-10
CL2014001651A1 (es) 2014-10-10
IL232905A (en) 2017-02-28
BR112014014454B1 (pt) 2021-03-09
AU2012354229A1 (en) 2014-06-05
ZA201403640B (en) 2017-06-28
JP6543467B2 (ja) 2019-07-10
JP2015500388A (ja) 2015-01-05
WO2013095279A1 (en) 2013-06-27
US20150011505A1 (en) 2015-01-08
EP2794665A1 (en) 2014-10-29
US9475888B2 (en) 2016-10-25
CN104144950A (zh) 2014-11-12
IL232905A0 (en) 2014-07-31
MX351104B (es) 2017-10-02
JP2018111825A (ja) 2018-07-19
SMT201800143T1 (it) 2018-05-02
CN104144950B (zh) 2017-09-05
RU2617764C2 (ru) 2017-04-26
RU2014129816A (ru) 2016-02-20
NO2904345T3 (enExample) 2018-07-21

Similar Documents

Publication Publication Date Title
SI2794665T1 (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
Wang et al. Chemical composition and moisture-absorption/retention ability of polysaccharides extracted from five algae
CY1112808T1 (el) Μειγματα ολιγοσακχαριτων προερχομενων απο την ηπαρινη, η παρασκευη τους και φαρμακευτικες συνθεσεις που τα περιεχουν
Smestad Paulsen Biologically active polysaccharides as possible lead compounds
SI2794667T1 (en) Low anticoagulant heparins
JP2015500388A5 (enExample)
Ciancia et al. Overview of anticoagulant activity of sulfated polysaccharides from seaweeds in relation to their structures, focusing on those of green seaweeds
Yu et al. Rhamnogalacturonan I domains from ginseng pectin
CZ307433B6 (cs) Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení
Krylov et al. Acid-promoted synthesis of per-O-sulfated fucooligosaccharides related to fucoidan fragments
CA2397964A1 (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
Revuelta et al. Heparanized chitosans: towards the third generation of chitinous biomaterials
Chaouch et al. Access to new anticoagulant by sulfation of pectin-like polysaccharides isolated from Opuntia ficus indica cladodes
HRP20230820T1 (hr) Heparan-sulfat, s visokom stopom 3-o-sulfatiranja u glukozaminskim ostacima
RU2014143008A (ru) Способ лечения остановки родов
DK3063177T3 (en) DERIVATIVES OF N-DESULPHATED GLYCOSAMINOGLYCANES AND USE AS MEDICINES
Song et al. Seaweed-derived fucoidans and rhamnan sulfates serve as potent anti-SARS-CoV-2 agents with potential for prophylaxis
JPH10218902A5 (enExample)
EP1745705A1 (en) Process for preparing uronic acid oligosaccharides by extrusion
JP2005536577A (ja) Ｎ−アシル−（エピ）ｋ５−アミン−ｏ−硫酸塩誘導体の製造方法およびｎ−アシル−（エピ）ｋ５−アミン−ｏ−硫酸塩誘導体
JP6784454B2 (ja) グリコサミノグリカンのカルボキシル化誘導体、及び薬物としての使用
RU2014149230A (ru) Лечение послеродового кровотечения (прк)
CN115485308A (zh) 制备低分子量肝素的方法以及由此获得的低分子量肝素
Driguez Synthesis of Natural and Nonnatural Heparin Fragments: Optimizations and Applications toward Modulation of FGF2‐Mediated FGFR Signaling
HK40004031A (en) Derivatives of n-desulfated glycosaminoglycans and use as drugs